Geneseeq and Zai Lab Announce Strategic Collaboration to Advance Cancer Drug R&D

Geneseeq与Zai Lab宣布战略合作推进癌症药物研发

2021-10-14 03:00:12 BioSpace

本文共1225个字,阅读需4分钟

Geneseeq Technology Inc. and Zai Lab, Ltd. announce new strategic collaboration in Shanghai, China. The companies will collaborate to facilitate the R&D and commercialization of Zai Lab's cancer drugs through business partnerships in clinical trial patient recruitment, central laboratory testing, companion diagnostics development and marketing activities. The announcement was made at the Zai Lab Innovation Summit on October 12th in Shanghai. Marc Zhao, the co-founder and Chief Operating Officer of Geneseeq delivered a keynote speech on the landscape of gastrointestinal tumor detection and diagnosis during the conference. To conclude, Zhao said that Geneseeq and Zai Lab hope to use this strategic collaboration as the cornerstone to combine resources of both companies to provide high-quality cancer diagnostics and treatment solutions. I look forward to further joint actions between the two parties to improve cancer patient outcomes and generate positive societal impact. William Liang , Chief Commercial Officer of Zai Lab and President of Greater China  said: "In recent years, advances in genetic testing technology have boosted the continuous improvement of precision medicine and treatment programs. Zai Lab has three products listed in China with 10-15 more products expected to be approved. Many of them rely on biomarker testing. We hope to work with genetic testing  partners to help patients achieve precise and personalized treatment. At the same time, we also look forward to working with these partners to improve the efficiency of drug research and development, shorten the development cycle, and accelerate product approvals." The companies look forward to a strong alliance in providing more accurate and efficient treatment plans for patients. About Geneseeq Geneseeq is a research-driven company providing cutting-edge NGS technology to accelerate precision cancer care, with headquarters located in Canada and China. The company offers both pan-cancer panels analyzing 400+ genes and cancer-type specific gene panels to help match patients to optimal treatments, including targeted therapy and immunotherapy. Their CAP/CLIA/ISO15189-accredited Chinese site is equipped with multiple advanced NGS sequencing platforms and has sequenced 500,000+ clinical samples. For more information, please follow Geneseeq on Linkedin and Twitter. About Zai Lab Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders and infectious disease. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide. For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global. View original content:https://www.prnewswire.com/news-releases/geneseeq-and-zai-lab-announce-strategic-collaboration-to-advance-cancer-drug-rd-301399328.html SOURCE Geneseeq Technology Inc.
Geneseeq科技公司和Zai Lab有限公司在中国上海宣布新的战略合作。两家公司将通过在临床试验患者招募、中央实验室测试、辅助诊断开发和营销活动方面的商业伙伴关系,合作促进Zai Lab癌症药物的研发和商业化。该声明是在10月12日于上海举行的Zai Lab创新峰会上发布的。 Geneseeq联合创始人兼首席运营官赵钊在大会期间发表了胃肠道肿瘤检测与诊断景观的主题演讲。Zhao最后表示,Geneseeq和Zai Lab希望以此次战略合作为基石,结合双方资源,提供高质量的癌症诊断和治疗解决方案。我期待双方进一步采取联合行动,改善癌症患者的结局,并产生积极的社会影响。 Zai Lab首席商务官兼大中华区总裁William Liang表示:“近年来,基因检测技术的进步助推了精准医学和治疗方案的不断完善。Zai Lab有三个产品在中国上市,预计还有10-15个产品将获得批准。他们中的许多人依赖于生物标志物测试。我们希望与基因检测合作伙伴一起,帮助患者实现精准个性化治疗。同时,我们也期待与这些合作伙伴一起,提高药物研发效率,缩短开发周期,加速产品审批。“ 两家公司期待强强联合,为患者提供更准确、高效的治疗方案。 关于Geneseeq Geneseeq是一家研究驱动的公司,提供尖端的NGS技术,以加速精准癌症护理,总部位于加拿大和中国。该公司提供分析400多个基因的泛癌症面板和癌症类型特定基因面板,以帮助患者匹配最佳治疗,包括靶向治疗和免疫治疗。他们的CAP/CLIA/ISO15189认证的中国网站配备了多个先进的NGS测序平台,已经对50多万份临床样本进行了测序。更多信息,请关注Linkedin和Twitter上的Geneseeq。 关于Zai实验室 Zai Lab(NASDAQ:ZLAB;HKEX:9688)是一家创新的、以研究为基础的、处于商业阶段的生物制药公司,专注于开发和商业化治疗方法,以解决肿瘤学、自身免疫疾病和传染病方面未满足的医疗条件。为此,我们经验丰富的团队与全球领先的生物制药公司建立了合作伙伴关系,以产生广泛的创新营销产品和候选产品。我们还建立了一个具有强大产品发现和转化研究能力的内部团队,并正在建立一个具有全球版权的专利候选产品管道。我们的愿景是成为全球领先的生物制药公司,发现、开发、制造和商业化我们的产品组合,以影响全球人类健康。 有关该公司的更多信息,请访问www.zailaboratory.com或在www.twitter.com/zailab_global关注我们。 查看原始内容:https://www.prnewswire.com/news-releases/geneseeq-and-zai-lab-announce-strategic-collaboration-to-advance-cancer-drug-rd-301399328.html 源Geneseeq技术公司。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文